UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naive Patient: A Comprehensive Review of the Literature

Pimolbutr, K; Porter, S; Fedele, S; (2018) Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naive Patient: A Comprehensive Review of the Literature. BioMed Research International , 2018 , Article 8071579. 10.1155/2018/8071579. Green open access

[img] Text
8071579.pdf - Published version

Download (1MB)

Abstract

Objectives. To review the available literature on medication-related osteonecrosis of the jaw (MRONJ) associated with antiangiogenics in antiresorptive-naïve individuals. Methods. A literature search was performed using MEDLINE via PubMed, EMBASE, and Web of Science in December 2017. Results. We identified reports describing a total of 35 antiresorptive drugs-naïve patients who developed antiangiogenic-related MRONJ. The mean age of these patients was 59.06 years and the F : M ratio was 4 : 5. The most common underlying disease was metastatic renal cell cancer. Pain to the mandible was the most common complaint (34.29%) and the majority of patients presented with bone exposure. The mean duration of intravenous and oral antiangiogenics before MRONJ development was 6.5 and 16.72 months, respectively. The most common additional risk factor was dental extraction (37.14%). Almost half of the MRONJ patients (48.57%) received surgical treatment. 18 patients (62.06%) were reported to have disease resolution within an average time of 6.75 months. Conclusion. MRONJ associated with antiangiogenic therapy in antiresorptive-naïve patients is a rare but potentially serious adverse effect. Available data suggests that there might be notable differences between MRONJ associated with antiangiogenics and antiresorptives; however, further prospective well-designed studies are required.

Type: Article
Title: Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naive Patient: A Comprehensive Review of the Literature
Open access status: An open access version is available from UCL Discovery
DOI: 10.1155/2018/8071579
Publisher version: https://doi.org/10.1155/2018/8071579
Language: English
Additional information: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Keywords: Science & Technology, Life Sciences & Biomedicine, Biotechnology & Applied Microbiology, Medicine, Research & Experimental, Research & Experimental Medicine, BISPHOSPHONATE-RELATED OSTEONECROSIS, MEDICATION-RELATED OSTEONECROSIS, SUNITINIB RELATED OSTEONECROSIS, SURGEONS POSITION PAPER, CANCER-PATIENTS, INHIBITOR TEMSIROLIMUS, AMERICAN ASSOCIATION, TREATMENT STRATEGIES, BEVACIZUMAB THERAPY, TARGETED AGENTS
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Eastman Dental Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Eastman Dental Institute > EDI MaxFac, Diagnostic, Med and Surg Sci
URI: https://discovery.ucl.ac.uk/id/eprint/10048842
Downloads since deposit
88Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item